ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0730

Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes

Michele Moretti1, Elena Elefante2, Francesco Ferro3, Ludovica Pisapia4, Federica Di Cianni5, Nazzareno Italiano6, ROSARIA TALARICO5, Chiara Baldini7 and Marta Mosca7, 1University of Pisa, Pisa, Pisa, Italy, 2Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Pisa, Italy, 3Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 4Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 5University of Pisa, Pisa, Italy, 6University of Pisa, Rovigo, Italy, 7University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, Patient reported outcomes, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA-associated vasculitides (AAVs) are characterized by severe and multisystemic manifestations that greatly affect patients’ quality of life (QoL). The purpose of the study was to assess QoL of AAVs patients on targeted therapy using patient-reported outcomes (PROs) and comparing the data obtained with clinical and biohumoral profile of patients.

Methods: A cross-sectional observational study was conducted between November 2023 and May 2024 on patients with a diagnosis of AAVs, made according to ACR/EULAR 2022 classification criteria, followed at our center and in remission (BVAS=0) for at least 6 month. All patients had been on a targeted therapy (Rituximab 500 mg/6 months or on-demand for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), Mepolizumab 300 mg/4 weeks for Eosinophilic Granulomatosis with Polyangiitis (EGPA)) for at least 6 months. The validated Italian version of Short Form Health Survey – 36 (SF-36), Hospital Anxiety and Depression Scale (HADS), Functional Assessment of Chronic Illness Therapy (FACIT), (ANCA-Associated Vasculitis – Patient Reported Outcome (AAV-PRO), Asthma Control Test (ACT) and Sino-Nasal Outcome Test – 22 (SNOT-22) questionnaires (the last two only in EGPAs) was administered. Demographic, clinical, and laboratory data of patients were collected and compared with indices obtained from PROs.

Results: Forty-five AAV patients were enrolled (8 MPA,14 GPA,23 EGPA), 57.8% (26/45) male. They showed a mean age of 61±12.1 years, a mean BVAS at diagnosis of 14.04±6.29 and a mean VDI at last follow-up of 3.3±2.2. 37.8% of patients were taking prednisone (mean daily dose of 3.77±1.30 mg). The characterization of patients by organ involvement can be seen in Figure 1. The mean values of indices obtained from PROs were: FACIT equal to 39.77±9.56, HADS-Anxiety 6.63±3.57, HADS-Depression 5.6±3.77, AAV-PRO SSS (Organ Specific and Systemic Symptoms and Signs) 9.37±7.80, AAV-PRO PF (Physical Function) 3.42±3.77 and AAV-PRO SEI (Social and Emotional Impact) 14.23±11.41. The results of the SF-36 subdomains are shown in Figure 2. The mean values of ACT and SNOT-22 for EGPA patients were 22.17±3.76 and 27.22±23.99, respectively.

PROs results were not correlated with vasculitis type, age, disease duration, prednisone current dose or disease-related organ involvement. The average value of VDI correlated negatively with FACIT (-0.3, p=0.04). In patients with EGPA, the presence of nasal polyposis was correlated with lower SF-36 scores in the subdomains of physical functioning, physical and emotional role limitations and energy (p=0.042, p=0.031, p=0.030, p=0.035, respectively), and severe asthma with lower values of the subdomain of general health (p=0.018).

Conclusion: AAVs patients in remission and on targeted therapy show a good quality of life, that is not dependent on disease phenotype and prior organ involvement but is partially influenced by chronic damage. The use of Mepolizumab in EGPA promotes a good subjective control of asthma and nasal polyposis, which are confirmed to be relevant factors in affecting quality of life. Further studies may evaluate the clinical utility of PROs for the characterization of response to therapies.

Supporting image 1

Figure 1. Patients profile by organ involvement

Supporting image 2

Figure 2. Results of SF_36 subdomains


Disclosures: M. Moretti: None; E. Elefante: None; F. Ferro: None; L. Pisapia: None; F. Di Cianni: None; N. Italiano: None; R. TALARICO: None; C. Baldini: Amgen, 1, 2, Aurinia, 1, GlaxoSmithKlein(GSK), 2, 5, 6, 12, Paid Instructor, johnson & johnson, 1, Novartis, 5, Sanofi, 2, 6, 12, Paid Instructor, Viela, 5; M. Mosca: AbbVie, 2, 6, AstraZeneca, 2, 6, GSK, 2, 5, 6, Idorsia, 2, Janssen, 6, Lilly, 6, Otsuka, 2, 6, UCB, 2.

To cite this abstract in AMA style:

Moretti M, Elefante E, Ferro F, Pisapia L, Di Cianni F, Italiano N, TALARICO R, Baldini C, Mosca M. Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/assessment-of-the-quality-of-life-in-a-single-center-cohort-of-patients-with-anca-associated-vasculitis-on-targeted-therapy-characterization-of-global-disease-and-organ-specific-parameters-using-pat/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-quality-of-life-in-a-single-center-cohort-of-patients-with-anca-associated-vasculitis-on-targeted-therapy-characterization-of-global-disease-and-organ-specific-parameters-using-pat/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology